Cargando…

870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)

BACKGROUND: Olorofim is a novel antifungal agent active against Aspergillus spp (including azole-resistant strains), rare, resistant moulds (e.g., Lomentospora prolificans) and dimorphic moulds. Serial images of Lomentospora prolificans infection following breast enhancement surgery: progression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Maertens, Johan A, Verweij, Paul E, Lanuza, Evan F, Harvey, Emma L, Dane, Aaron, Zinzi, Daniela, Rex, John H, Chen, Sharon C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752288/
http://dx.doi.org/10.1093/ofid/ofac492.063
_version_ 1784850684074524672
author Maertens, Johan A
Verweij, Paul E
Lanuza, Evan F
Harvey, Emma L
Dane, Aaron
Zinzi, Daniela
Rex, John H
Chen, Sharon C
author_facet Maertens, Johan A
Verweij, Paul E
Lanuza, Evan F
Harvey, Emma L
Dane, Aaron
Zinzi, Daniela
Rex, John H
Chen, Sharon C
author_sort Maertens, Johan A
collection PubMed
description BACKGROUND: Olorofim is a novel antifungal agent active against Aspergillus spp (including azole-resistant strains), rare, resistant moulds (e.g., Lomentospora prolificans) and dimorphic moulds. Serial images of Lomentospora prolificans infection following breast enhancement surgery: progression of healing pre- and post-olorofim therapy. [Figure: see text] Post-surgical bone/ soft tissue Lomentospora prolificans infection of the chest wall in a healthy woman was uncontrolled with available agents (D -9 visible mould in wound base). At D42/84 overall response on olorofim monotherapy was stable; wound closure with complete resolution of IFI was achieved at D322 (case previously reported, ECCMID 2020 abstract #2585). METHODS: Patients with limited/no treatment options for proven invasive fungal infection (IFI) or probable pulmonary invasive aspergillosis (IA) using EORTC-MSGERC criteria(1) received oral olorofim (150mg BID x1d loading dose then 90mg BID). Outcomes in the first 100 patients are compared with historical controls (HCs) as well as with expected outcomes in patients with baseline highly active, uncontrolled IFI (HAU-IFI). RESULTS: All-cause mortality in IA at month 3 (includes data to Day 100, the best-fit time point for IA HC data) was 17/53 (32%, 95 CI 20–46%) for olorofim vs. 40/46 (87%, 74–95%) in HCs given either no therapy or azole monotherapy for azole-resistant IA. Successful EORTC-MSGERC overall response(2) (OR, complete or partial based on clinical + radiologic + mycologic improvement) was 47%/42% in IA (Day 42/D84, n = 53), 53%/53% (L. prolificans, n=17), 55%/36% (Scedosporium, n=11), and 50%/50% (other moulds, n=8). Stable response at D42/D84 predicted extended therapy responses, especially in HAU-IFI of brain and bone (Figure). For Coccidioides (n=11) OR was limited to stable due to very slow clearance of fungal serology but clinical response was rapid. Symptoms resolved completely in 18% (2/11) by D84 vs 3% (1/29) by D1523 in comparable HCs with poorly controlled extrapulmonary Coccidioides infection; similar trends were seen for other response measures. CONCLUSION: Olorofim is a novel oral antifungal with activity against a wide range of mould infections which are difficult to treat. Compared with relevant HCs or expected outcomes for HAU-IFI, olorofim has a positive benefit-risk profile in a well-defined population of patients with limited/no treatment options. As noted previously(3), considering stable in overall success if often appropriate when assessing responses in non-IA mould IFI. References: 1. Donnelly CID 2020; 71:1367–76 2. Segal CID 2008; 47:674–83 3. Perfect Mycoses 2018: 61:420 DISCLOSURES: Johan A. Maertens, MD PhD, F2G Ltd: Advisor/Consultant|Gilead Sciences Ltd: Advisor/Consultant|Mundipharma: Advisor/Consultant|Pfizer Inc: Advisor/Consultant Paul E. Verweij, PhD, Gilead: Grant/Research Support Emma L. Harvey, MBBS, F2G Ltd: Stocks/Bonds Aaron Dane, MSc, Amplyx: Advisor/Consultant|AN2 therapeutics: Advisor/Consultant|Artizan: Advisor/Consultant|Cidara: Advisor/Consultant|ContraFect: Advisor/Consultant|Correvio: Advisor/Consultant|Davolterra: Advisor/Consultant|Destiny Pharma: Advisor/Consultant|Entasis: Advisor/Consultant|F2G Limited: Advisor/Consultant|GSK: Advisor/Consultant|Humanigen: Advisor/Consultant|Kymab: Advisor/Consultant|Modis: Advisor/Consultant|Orca: Advisor/Consultant|Pfizer: Advisor/Consultant|Phico: Advisor/Consultant|Pled Pharma: Advisor/Consultant|Rare Thyroid: Advisor/Consultant|Roche: Advisor/Consultant|Scynexis: Advisor/Consultant|Sinovent: Advisor/Consultant|Spero Therapeutics: Advisor/Consultant|Transcrip: Advisor/Consultant|Venatorx: Advisor/Consultant Daniela Zinzi, Infectious Diseases Specialist, F2G: F2G employee|F2G: Stocks/Bonds John H. Rex, MD, Advent Life Sciences: Operating Partner|Advent Life Sciences: Ownership Interest|AMR Action Fund: Advisor/Consultant|AstraZeneca: Stocks/Bonds|Basilea Pharmaceutica: Advisor/Consultant|Bugworks Research, Inc.: Advisor/Consultant|F2G, Limited: Employee|F2G, Limited: Stocks/Bonds|Forge Therapeutics: Advisor/Consultant|GlaxoSmithKline: Advisor/Consultant|Pfizer Pharmaceuticals: Honoraria|Sumitovant: Advisor/Consultant Sharon C. Chen, PhD MBBS, F2G PTy Ltd: Grant/Research Support|MSD Australia: Grant/Research Support.
format Online
Article
Text
id pubmed-9752288
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97522882022-12-16 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32) Maertens, Johan A Verweij, Paul E Lanuza, Evan F Harvey, Emma L Dane, Aaron Zinzi, Daniela Rex, John H Chen, Sharon C Open Forum Infect Dis Abstracts BACKGROUND: Olorofim is a novel antifungal agent active against Aspergillus spp (including azole-resistant strains), rare, resistant moulds (e.g., Lomentospora prolificans) and dimorphic moulds. Serial images of Lomentospora prolificans infection following breast enhancement surgery: progression of healing pre- and post-olorofim therapy. [Figure: see text] Post-surgical bone/ soft tissue Lomentospora prolificans infection of the chest wall in a healthy woman was uncontrolled with available agents (D -9 visible mould in wound base). At D42/84 overall response on olorofim monotherapy was stable; wound closure with complete resolution of IFI was achieved at D322 (case previously reported, ECCMID 2020 abstract #2585). METHODS: Patients with limited/no treatment options for proven invasive fungal infection (IFI) or probable pulmonary invasive aspergillosis (IA) using EORTC-MSGERC criteria(1) received oral olorofim (150mg BID x1d loading dose then 90mg BID). Outcomes in the first 100 patients are compared with historical controls (HCs) as well as with expected outcomes in patients with baseline highly active, uncontrolled IFI (HAU-IFI). RESULTS: All-cause mortality in IA at month 3 (includes data to Day 100, the best-fit time point for IA HC data) was 17/53 (32%, 95 CI 20–46%) for olorofim vs. 40/46 (87%, 74–95%) in HCs given either no therapy or azole monotherapy for azole-resistant IA. Successful EORTC-MSGERC overall response(2) (OR, complete or partial based on clinical + radiologic + mycologic improvement) was 47%/42% in IA (Day 42/D84, n = 53), 53%/53% (L. prolificans, n=17), 55%/36% (Scedosporium, n=11), and 50%/50% (other moulds, n=8). Stable response at D42/D84 predicted extended therapy responses, especially in HAU-IFI of brain and bone (Figure). For Coccidioides (n=11) OR was limited to stable due to very slow clearance of fungal serology but clinical response was rapid. Symptoms resolved completely in 18% (2/11) by D84 vs 3% (1/29) by D1523 in comparable HCs with poorly controlled extrapulmonary Coccidioides infection; similar trends were seen for other response measures. CONCLUSION: Olorofim is a novel oral antifungal with activity against a wide range of mould infections which are difficult to treat. Compared with relevant HCs or expected outcomes for HAU-IFI, olorofim has a positive benefit-risk profile in a well-defined population of patients with limited/no treatment options. As noted previously(3), considering stable in overall success if often appropriate when assessing responses in non-IA mould IFI. References: 1. Donnelly CID 2020; 71:1367–76 2. Segal CID 2008; 47:674–83 3. Perfect Mycoses 2018: 61:420 DISCLOSURES: Johan A. Maertens, MD PhD, F2G Ltd: Advisor/Consultant|Gilead Sciences Ltd: Advisor/Consultant|Mundipharma: Advisor/Consultant|Pfizer Inc: Advisor/Consultant Paul E. Verweij, PhD, Gilead: Grant/Research Support Emma L. Harvey, MBBS, F2G Ltd: Stocks/Bonds Aaron Dane, MSc, Amplyx: Advisor/Consultant|AN2 therapeutics: Advisor/Consultant|Artizan: Advisor/Consultant|Cidara: Advisor/Consultant|ContraFect: Advisor/Consultant|Correvio: Advisor/Consultant|Davolterra: Advisor/Consultant|Destiny Pharma: Advisor/Consultant|Entasis: Advisor/Consultant|F2G Limited: Advisor/Consultant|GSK: Advisor/Consultant|Humanigen: Advisor/Consultant|Kymab: Advisor/Consultant|Modis: Advisor/Consultant|Orca: Advisor/Consultant|Pfizer: Advisor/Consultant|Phico: Advisor/Consultant|Pled Pharma: Advisor/Consultant|Rare Thyroid: Advisor/Consultant|Roche: Advisor/Consultant|Scynexis: Advisor/Consultant|Sinovent: Advisor/Consultant|Spero Therapeutics: Advisor/Consultant|Transcrip: Advisor/Consultant|Venatorx: Advisor/Consultant Daniela Zinzi, Infectious Diseases Specialist, F2G: F2G employee|F2G: Stocks/Bonds John H. Rex, MD, Advent Life Sciences: Operating Partner|Advent Life Sciences: Ownership Interest|AMR Action Fund: Advisor/Consultant|AstraZeneca: Stocks/Bonds|Basilea Pharmaceutica: Advisor/Consultant|Bugworks Research, Inc.: Advisor/Consultant|F2G, Limited: Employee|F2G, Limited: Stocks/Bonds|Forge Therapeutics: Advisor/Consultant|GlaxoSmithKline: Advisor/Consultant|Pfizer Pharmaceuticals: Honoraria|Sumitovant: Advisor/Consultant Sharon C. Chen, PhD MBBS, F2G PTy Ltd: Grant/Research Support|MSD Australia: Grant/Research Support. Oxford University Press 2022-12-15 /pmc/articles/PMC9752288/ http://dx.doi.org/10.1093/ofid/ofac492.063 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Maertens, Johan A
Verweij, Paul E
Lanuza, Evan F
Harvey, Emma L
Dane, Aaron
Zinzi, Daniela
Rex, John H
Chen, Sharon C
870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
title 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
title_full 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
title_fullStr 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
title_full_unstemmed 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
title_short 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32)
title_sort 870. olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: comparison of interim results from a phase 2b open-label study with outcomes in historical control populations (nct03583164, formula-ols, study 32)
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752288/
http://dx.doi.org/10.1093/ofid/ofac492.063
work_keys_str_mv AT maertensjohana 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT verweijpaule 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT lanuzaevanf 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT harveyemmal 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT daneaaron 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT zinzidaniela 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT rexjohnh 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32
AT chensharonc 870olorofimforthetreatmentofinvasivemouldinfectionsinpatientswithlimitedornotreatmentoptionscomparisonofinterimresultsfromaphase2bopenlabelstudywithoutcomesinhistoricalcontrolpopulationsnct03583164formulaolsstudy32